Surgical decisions made by 158 women with hereditary breast cancer aged <50 years

被引:35
作者
Evans, DGR
Lalloo, F
Hopwood, P
Maurice, A
Baildam, A
Brain, A
Barr, L
Howell, A
机构
[1] St Marys Hosp, Acad Unit Med Genet, Manchester M13 0JH, Lancs, England
[2] St Marys Hosp, Reg Genet Serv, Manchester M13 0JH, Lancs, England
[3] S Manchester Univ Hosp Trust, Withington Hosp, Nightingale Ctr, Breast Canc Family Hist Clin, Manchester, Lancs, England
[4] Christie Hosp, Dept Psychol Med, Manchester M20 9BX, Lancs, England
[5] Christie Hosp, Dept Plast Surg, Manchester M20 9BX, Lancs, England
[6] S Manchester Univ Hosp Trust, Dept Surg, Manchester, Lancs, England
[7] Christie Hosp, Dept Med Oncol, Manchester, Lancs, England
来源
EJSO | 2005年 / 31卷 / 10期
关键词
BRCA1; BRCA2; risk-reducing mastectomy; contralateral;
D O I
10.1016/j.ejso.2005.05.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To establish the uptake of contralateral risk reducing mastectomy in women informed of their risks and options at time of diagnosis of their primary unilateral breast cancer. Methods: We have assessed the surgical choices of 70 women diagnosed with breast cancer <50 years as part of a family history surveillance program and fully informed about their contralateral. risks and surgical options. We have compared this to women from other surgical clinics who were subsequently found to harbour a pathogenic BRCA1/2 mutation. Results: Sixty-five percent (13/20) of BRCA1/2 mutation carriers and 59% (n=20/34) of those at the highest level of risk pre-diagnosis (33+% lifetime risk) opted for contra-lateral mastectomy in the study sample. In contrast only 10% (n=9/88) women identified as mutation carriers from other clinics opted for such surgery. Conclusions: We would suggest that women with a significant family history and therefore a high contra-lateral breast cancer risk, should have these risks and management options discussed at the time of diagnosis of breast cancer. (C) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1112 / 1118
页数:7
相关论文
共 33 条
  • [1] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
    Antoniou, A
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Loman, N
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1117 - 1130
  • [2] Baum M, 2003, Cancer, V98, P1802
  • [3] Changes in psychological distress after cancer genetic counselling: a comparison of affected and unaffected women
    Bish, A
    Sutton, S
    Jacobs, C
    Levene, S
    Ramirez, A
    Hodgson, S
    [J]. BRITISH JOURNAL OF CANCER, 2002, 86 (01) : 43 - 50
  • [4] CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO
  • [5] 2-5
  • [6] Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation
    Contant, CME
    Menke-Pluijmers, MBE
    Seynaeve, C
    Meijers-Heijboer, EJ
    Klijn, JGM
    Verhoog, LC
    Wai, RTJ
    Eggermont, AMM
    van Geel, AN
    [J]. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2002, 28 (06): : 627 - 632
  • [7] Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility:: Findings from p53 and BRCA1 testing programs
    Dorval, M
    Patenaude, AF
    Schneider, KA
    Kieffer, SA
    DiGianni, L
    Kalkbrenner, KJ
    Bromberg, JI
    Basili, LA
    Calzone, K
    Stopfer, J
    Weber, BL
    Garber, JE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) : 2135 - 2142
  • [8] EASTON DF, 1995, AM J HUM GENET, V56, P265
  • [9] Familial breast cancer: An investigation into the outcome of treatment for early stage disease
    Eccles D.
    Simmonds P.
    Goddard J.
    Coultas M.
    Hodgson S.
    Lalloo F.
    Evans G.
    Haites N.
    [J]. Familial Cancer, 2001, 1 (2) : 65 - 72
  • [10] The pathology of familial breast cancer:: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2
    Lakhani, SR
    van de Vijver, MJ
    Jacquemier, J
    Anderson, TJ
    Osin, PP
    McGuffog, L
    Easton, DF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (09) : 2310 - 2318